Panelists discuss how first-line targeted therapy for advanced melanoma, particularly BRAF and MEK inhibitors, may offer significant benefits in patients with BRAF-mutant tumors, emphasizing rapid response and the potential for combination with immunotherapy to improve long-term outcomes.
Of Interest
UTSW scientists identify cancer-suppressing genetic mutation
DALLAS – Dec. 23, 2024 – UT Southwestern Medical Center researchers identified a genetic mutation that slows the growth of melanoma and potentially other cancers by harnessing the power of the immune system.
Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
Insight on Treating Patients With Melanoma With Brain Metastases
Panelists discuss how treating patients with melanoma and brain metastases requires a multidisciplinary approach, emphasizing the role of immunotherapy, targeted therapy, and local treatments, while considering factors like the extent of metastasis and patient-specific factors.